Creo Medical Group PLC
LSE:CREO

Watchlist Manager
Creo Medical Group PLC Logo
Creo Medical Group PLC
LSE:CREO
Watchlist
Price: 16 GBX Market Closed
Market Cap: 65.9m GBX
Have any thoughts about
Creo Medical Group PLC?
Write Note

Creo Medical Group PLC
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Creo Medical Group PLC
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Creo Medical Group PLC
LSE:CREO
Net Change in Cash
-ÂŁ1.6m
CAGR 3-Years
66%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Smith & Nephew PLC
LSE:SN
Net Change in Cash
$362m
CAGR 3-Years
-30%
CAGR 5-Years
55%
CAGR 10-Years
N/A
LivaNova PLC
NASDAQ:LIVN
Net Change in Cash
$133.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
21%
EKF Diagnostics Holdings PLC
LSE:EKF
Net Change in Cash
ÂŁ655k
CAGR 3-Years
-45%
CAGR 5-Years
-25%
CAGR 10-Years
-22%
Angle PLC
LSE:AGL
Net Change in Cash
-ÂŁ4.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
B
Belluscura PLC
LSE:BELL
Net Change in Cash
-$1.1m
CAGR 3-Years
-29%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Creo Medical Group PLC
Glance View

Market Cap
65.9m GBX
Industry
Health Care

Creo Medical Group Plc operates as a medical device company that focuses on surgical endoscopy. The company is headquartered in Chepstow, Monmouthshire/Sir Fynwy and currently employs 245 full-time employees. The company went IPO on 2016-12-09. The firm focuses on the field of surgical endoscopy. The company is focused on the development and commercialization of minimally invasive electrosurgical devices. The firm has developed CROMA, which delivers bipolar radiofrequency (RF) energy for precise localized cutting and focused microwave (MW) energy for controlled coagulation and ablation through a single accessory port. The company has three initial areas of clinical focus, which include in the Gastrointestinal (GI) tract, soft tissue ablation (including but not limited to the liver, pancreas, kidney), and lung interventions for the resection and/or ablation of precancerous and cancerous lesions. The firm has four technology families, which include Speedboat, MicroBlate, SlypSeal and SpydrBlade.

CREO Intrinsic Value
25.93 GBX
Undervaluation 38%
Intrinsic Value
Price

See Also

What is Creo Medical Group PLC's Net Change in Cash?
Net Change in Cash
-1.6m GBP

Based on the financial report for Jun 30, 2024, Creo Medical Group PLC's Net Change in Cash amounts to -1.6m GBP.

What is Creo Medical Group PLC's Net Change in Cash growth rate?
Net Change in Cash CAGR 3Y
66%

Over the last year, the Net Change in Cash growth was 89%. The average annual Net Change in Cash growth rates for Creo Medical Group PLC have been 66% over the past three years .

Back to Top